GlassScriptPhysician profile
Efrosini Barish
NPI 1578500997
$3,532.07
in general payments reported to CMS, 2019-2025
30 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $120 · 2021: $154 · 2022: $214 · 2023: $320 · 2024: $860 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,639.26 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $481.48 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $402.70 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $338.65 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $312.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $254.02 | 2022-2025 | Cardiomems, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.31 | 2020-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $189.13 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $153.73 | 2019-2025 | |
| Stryker Corporation | $121.02 | 2025 | Blueprint Patient Specific Instrumentation |
| Bayer Healthcare Pharmaceuticals INC. | $117.70 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $105.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $74.39 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $70.01 | 2024-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $65.84 | 2019-2024 | Veozah |
| Sumitomo Pharma America, INC. | $65.72 | 2023-2025 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $64.15 | 2019-2022 | |
| Mannkind Corporation | $63.53 | 2025 | |
| Glaxosmithkline, LLC. | $60.65 | 2019-2024 | Arexvy |
| Janssen Pharmaceuticals, INC | $59.43 | 2019-2020 | |
| Amarin Pharma, INC. | $49.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $45.93 | 2024-2025 | Breztri |
| Medtronic, INC. | $45.10 | 2022 | |
| Idorsia Pharmaceuticals US INC | $41.16 | 2023-2024 | Quviviq |
| Seqirus USA INC | $26.46 | 2025 | Fluad, Flucelvax |
| Corcept Therapeutics | $26.41 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $23.19 | 2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $22.73 | 2020 | |
| Cardiovascular Systems INC. | $21.39 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.73 | 2019 | |
| Dexcom, INC. | $17.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrosini Barish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.